List of Tables
Pfizer Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Pfizer Inc, Deals By Therapy Area, 2012 to YTD 2018 23
Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25
Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26
Pfizer to Acquire Neksium Brand from AstraZeneca 50
Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 53
Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 54
Medivation Acquires Rights to Talazoparib from BioMarin Pharma 55
Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 56
Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 57
Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 58
Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 60
Pfizer Acquires Melanocortin Receptors from MRC Technology 62
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 63
Pfizer Completes Acquisition Of Polocard From Polpharma For US$32 Million 64
Morphic Therapeutic Raises USD80 Million in Series B Financing 65
Biodesy Raises USD20 Million in Series C Venture Financing 67
4D Molecular Therapeutics Raises USD90 Million in Series B Venture Financing 68
Artios Pharma Raises USD83.6 Million in Series B Venture Financing 70
Therachon Raises USD60 Million in Mezzanine Financing 72
Nimbus Therapeutics Raises USD65 Million in Financing 74
Cortexyme Raises USD76 Million in Series B Venture Financing 76
Strata Oncology Raises USD26 Million in Series B Venture Financing 78
Allogene Therapeutics to Raise USD300 Million in Series A Financing 80
Adapsyn Bioscience Raises Funds through Venture Financing 82
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 83
Cydan Raises USD34 Million in Venture Financing 85
Palleon Pharma Raises USD47.6 Million in Series A Financing 86
SpringWorks Therapeutics Raises USD103 Million in Series A Financing 87
Complexa Raises USD62 Million in Series C Financing 89
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 90
Neuronetics Raises USD15 Million in Series G Round of Financing 92
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 94
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 96
Circle Pharma Raises Funds through Series A Preferred Stock Financing 98
Ixchelsis Raises Additional USD12 Million in Venture Financing 99
Vtesse Raises USD17 Million in Extended Series A Financing 100
Second Genome Raises USD8.4 Million in Extended Series B Financing 101
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 102
Storm Therapeutics Raises USD16 Million in Series A Venture Financing 104
Blade Therapeutics Raises USD27 Million in Series B Financing 105
Second Genome Raises USD42.6 Million in Series B Financing 107
Cydan Development Raises USD31 Million in Series A Financing 109
Metabomed Raises USD18 Million in Series A Venture Financing 110
Mission Therapeutics Raises USD85.7 Million in Financing Round 111
Biodesy Raises USD10 Million in Series B Financing 112
Lodo Therapeutics Raises USD17 Million in Series A Financing 113
Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 115
NextCure Raises USD67 Million in Series A Financing 116
Petra Pharma Raises USD48 Million in Series A Financing 118
Cortexyme Raises USD15 Million in Series A Financing Round 120
Merus Raises USD46.4 Million in First Tranche of Series C Financing 121
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 123
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 125
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 126
Nimbus Therapeutics Raises USD43 Million in Series B Financing 128
Mersana Therapeutics Raises USD35 Million in Series B Financing 130
Vtesse Raises USD25 Million in Series A Financing 131
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 132
Ziarco Raises USD33 Million in Series B Venture Financing 133
Quartet Medicine Raises USD17 Million in Series A Venture Financing 134
Circle Pharma Raises Funds through Seed Financing 135
Epic Sciences Raises USD30 Million in Series C Venture Financing 136
NexImmune Raises USD3 Million in Venture Financing 137
Mission Therapeutics Raises US$32 Million In Series B Financing 138
Biodesy Raises US$15 Million In Series A Financing 139
Merus Raises US$42 Million In Extended Series B Financing 140
Cydan Raises US$26 Million In Venture Financing 142
Esperion Therapeutics Raises US$33 Million In Venture Financing 144
Aquinox Pharma Raises US$18 Million In Series C Financing 146
Esperion Therapeutics Raises US$1 Million In Venture Financing 147
Flexion Therapeutics Raises USD20 Million In Series B Financing 148
Rhythm Pharma Raises US$33 Million In Series B Financing 149
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 151
Epic Sciences Raises US$13 Million In Series B Financing 153
Ziarco Pharma Raises US$6 Million In First Tranche Of Series A financing 154
Mirna Therapeutics Raises US$34 Million In Series C Financing 155
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 157
InnoPharma Raises US$8 Million In Venture Financing 159
Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 160
Celladon Raises Additional US$10 Million In Series D Financing 161
Bain Capital May Acquire Laboratorio Teuto Brasileiro 163
Pfizer Enters into Licensing Agreement with Scripps Research Institute 164
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 165
Nektar Therapeutics Enters into Collaboration Agreement with Pfizer 166
Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 167
Pfizer Enters into Co-Development Agreement with Novartis 168
Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 169
Bain Capital and Pfizer Form Joint Venture 170
Myriad Genetics and Pfizer Enter into Agreement 171
Calithera Biosciences Enters into Partnership with Pfizer 172
Atomwise Enters into Evaluation Agreement with Pfizer 173
CYTOO Enters into Research and Option Agreement with Pfizer 174
Checkmate Pharma Enters into Partnership with Merck and Pfizer 175
BioNTech Enters into R&D Agreement with Pfizer 176
Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 177
Vyriad Enters into Collaboration Agreement with Merck and Pfizer 178
XtalPi Enters into Research Agreement with Pfizer 179
BioDuro Enters into Agreement with Pfizer 180
Neofluidics Enters into Agreement with Pfizer 181
NetVation DL Medicine Enters into Research Agreement with Pfizer 182
MindImmune Therapeutics Enters into Research Agreement with Pfizer 183
Kite Pharma Enters into Partnership with Pfizer 184
Adapsyn Bioscience Enters into Research Agreement with Pfizer 185
Array BioPharma Enters into Agreement with Pfizer 186
Encycle Therapeutics Enters into Research Agreement with Pfizer 187
Themis Medicare Forms Joint Venture Agreement with Global Pharmatech 188
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 189
Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 190
Alcyone Lifesciences Enters into Agreement with Pfizer 191
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 192
Astellas Pharma Amends Agreement with Pfizer 193
EpiThany Enters into Agreement with Merck and Pfizer 194
VAXIMM Enters into Agreement with Merck and Pfizer 195
Domain Therapeutics Enters into Partnership with Pfizer 196
Pfizer Enters into Agreement with Washington University in St. Louis 197
Edelris Enters into Research Agreement with Pfizer 198
AbCellera Biologics Enters into Research Agreement with Pfizer 199
Pfizer Partners with NovaMedica 200
PegBio Partners with Pfizer 201
Pfizer Enters into Agreement with National Cancer Institute 202
Debiopharm Partners with Merck and Pfizer 203
Transgene Enters into Agreement with Merck and Pfizer 204
Circle Pharma Partners with Pfizer 205
Pfizer and CR Saike Pharma Enter into Distribution Agreement 206
Pfizer Partners with inVentiv Health 207
Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 208
BioRap Technologies Enters into Co- Development Agreement with Pfizer 209
Pfizer Enters into Agreement with NovaQuest Capital Management 210
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 211
Merck, Pfizer and Verastem Enter into Agreement 212
Pfizer Enters into Partnership Agreement with RPI Finance Trust 213
Pfizer Enters into Agreement with California Institute for Biomedical Research 214
Pfizer Enters into Research Agreement with Adaptive Biotech 215
Merck, Pfizer and Syndax Pharma Enter into Agreement 216
Heptares Therapeutics Enters into Agreement with Pfizer 217
Pfizer Enters into Agreement with Biovac Institute 218
Pfizer Enters into Agreement with GlaxoSmithKline 219
Pfizer Enters into Agreement with Synthon 220
Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 221
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 222
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 223
Regimmune Enters into Research Agreement with JDRF and Pfizer 224
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 225
HiFiBiO Enters into Research Agreement with Pfizer 226
Pharmacosmos Enters into Agreement with Pfizer 227
Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 228
University of Dundee Enters into Research Agreement with Pfizer 229
HemoShear Enters into Agreement with Pfizer 230
Pfizer Enters into Co-Development Agreement with Merck 231
Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 233
Crohn’s & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 234
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 235
X-Chem Enters into Co-Development Agreement with Pfizer 237
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 238
Cambridge University, Imperial College London, King’s College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 239
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 241
BioRestorative Therapies Enters into Research Agreement with Pfizer 242
Process Systems Enters Into Co-Development Agreement With Pfizer 243
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 244
Octapharma Enters Into Co-Marketing Agreement With Pfizer 245
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 246
Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 247
Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 248
Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 249
Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 250
Centers For Therapeutic Innovation Partners with UC San Francisco 251
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 252
Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 253
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 254
OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 255
Humedica Enters Into Agreement With Pfizer 257
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 258
Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 259
Apredica Enters Into Research Agreement With Pfizer 260
Mochida Pharma Enters Into Agreement With Hospira Japan To Distribute And Promote Oncology Products 261
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 262
Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 263
SFJ Pharma Enters Into Co-Development Agreement With Pfizer For Dacomitinib 264
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 265
Nodality Enters Into Agreement With Pfizer For Single Cell Network Profiling Technology 266
Pfizer Enters Into Co-Development Agreement With Harvard University 267
Cold Spring Harbor Labs Enters Into Research Agreement With Pfizer For New Cancer Therapies 268
Ildong Pharma Enters Into Co-Promotion Agreement With Pfizer Pharma For Generic Drugs 269
Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 270
Pfizer Enters into Co-Promotion Agreement with Specpharm 271
Pfizer Plans To Enter Into Co-Development Agreement With India-Based Pharma Company 272
Pfizer Enters Into Co-Marketing Agreement With Biologics For Inlyta 273
KineMed Extends Research Agreement With Pfizer 274
ICM Enters into Research Collaboration with Pfizer 275
KineMed Enters Into Co-Development Agreement With Pfizer 276
SFJ Pharma Enters Into Co-Development Agreement With Pfizer 277
Pfizer Enters into Licensing Agreement with Cancer Therapeutics CRC 278
Pfizer Amends Licensing Agreement with Spark Therapeutics 279
Allogene Therapeutics Enters into Licensing Agreement with Pfizer 281
Suzhou Kintor Pharma Enters into Licensing Agreement with Pfizer 282
Imcyse Research Agreement with Pfizer 283
Pfizer Enters into Licensing Agreement with Distributed Bio for SuperHuman Platform 284
Pfizer Enters into Licensing Agreement with Berkeley Lights 285
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 286
Pfizer Enters into Licensing Agreement with Arvinas 287
SpringWorks Therapeutics Receives Rights from Pfizer 288
Pfizer Amends Licensing Agreement with Basilea Pharma 289
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 290
Pfizer Enters into Licensing Agreement with HitGen 291
Absorption Systems Enters into Licensing Agreement with Pfizer 292
Pfizer Enters into Licensing Agreement with BioInvent International 293
Pfizer Enters into Licensing Agreement with Ab Initio Biotherapeutics 294
Pfizer Enters into Licensing Agreement with OncoImmune 295
Pfizer Enters into Option Agreement with AnTolRx 296
Pfizer Enters into Licensing Agreement with Western Oncolytics 297
Shire Enters into Licensing Agreement with Pfizer 298
Pfizer Enters into Licensing Agreement with WAVE Life Sciences 299
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 300
Pfizer Enters into Licensing Agreement with 4D Molecular Therapeutics 302
Pfizer Enters into Licensing Agreement with BioAtla 303
Pfizer Enters into Licensing Agreement with Servier for UCART19 304
Iterum Therapeutics Enters into Licensing Agreement with Pfizer 305
Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 306
Clinigen Extends Licensing Agreement with Hospira for Foscavir 307
Opko Health Enters into Licensing Agreement with Pfizer 308
Philogen Exercises Option for Licensing Agreement with Pfizer 310
Medivation Exercises Option for Licensing Agreement with CureTech for Pidilizumab 311
iTeos Therapeutics Enters into Licensing Agreement with Pfizer 313
MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer 314
Tabuk Pharma Enters into Licensing Agreement with Pfizer 315
Pfizer Enters into Licensing Agreement with Cellectis 316
Champions Oncology Enters into Licensing Agreement with Pfizer 317
IRICoR And University Of Montreal Enter Into Licensing Agreement With Pfizer 318
Gliknik Enters Into Licensing Agreement With Pfizer For GL-2045 320
Bioventus Enters Into Licensing Agreement With Pfizer For Bone Morphogenetic Protein Portfolio 321
Hospira Enters into Licensing Agreement with NovaQuest for Pegylated Filgrastim 322
Hospira Enters into Licensing Agreement with NovaQuest for Erythropoietin Biosimilar 323
Hospira Enters into Licensing Agreement with NovaQuest for Filgrastim 325
Philogen Enters Into Licensing Agreement With Pfizer For Dekavil 326
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 327
Ziarco Pharma Enters Into Licensing Agreement With Pfizer 328
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 329
AstraZeneca Enters Into Licensing Agreement With Pfizer For Nexium 330
Pfizer Enters Into Licensing Agreement With Biocad For Hemophilia Drug 332
Verastem Enters into Licensing Agreement with Pfizer 333
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 334
Pfizer Enters Into Licensing Agreement With SatRx For PF-00734200 335
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 336
Pfizer Enters into Licensing Agreement with KineMed 337
Pfizer Enters into Licensing Agreement with Evotec 338
Tris Pharma Enters into Licensing Agreement with Pfizer Consumer Healthcare 339
Genedata Enters into Licensing Agreement with Pfizer 340
Absorption Systems Enters into Licensing Agreement with Pfizer 341
Orion And Hospira Extend Licensing Agreement For Precedex 342
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 343
Harbour Antibodies Enters Into Licensing Agreement With Pfizer For Human Monoclonal Antibodies 344
Sequella Enters Into Licensing Agreement With Pfizer For Sutezolid 345
Abcam Enters Into Licensing Agreement With Pfizer 346
Tetragenetics Enters Into Option For Licensing Agreement With Pfizer For SionX Technology 347
VLST Enters Into Licensing Agreement With Pfizer For Anti-CD40 Monoclonal Antibody 348
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 349
Quark Pharma Amends Licensing Agreement With Pfizer For PF-655 351
FAES Farma And Pfizer Expand Bilastine License Agreement To 21 New Markets In Latin America 352
Pfizer Files Registration Statement for Public Offering of Securities 353
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 354
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 356
AnTolRx to Raise USD4 Million in Private Placement of Shares 357
Western Oncolytics Raises Funds in Private Placement of Shares 358
Sosei Group Raises USD33 Million in Private Placement of Shares 359
Protalix BioTherapeutics Raises USD10 Million in Private Placement of Shares 360
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 361
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 363
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 365
Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$70 Million 366
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 368
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 369
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 370
Pfizer Raises USD0.3 Billion in Public Offering of Floating Rate Notes Due 2023 372
Pfizer Raises USD0.7 Billion in Public Offering of 4.1% Notes Due 2038 374
Pfizer Raises USD1 Billion in Public Offering of 3.2% Notes Due 2023 376
Pfizer Raises USD1 Billion in Public Offering of 4.2% Notes Due 2048 378
Pfizer Raises USD1 Billion in Public Offering of 3.6% Notes Due 2028 380
Pfizer Raises USD1 Billion in Public Offering of 3% Notes Due 2021 382
Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 384
Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 386
Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 388
Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 390
Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 392
Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 394
Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 396
Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 398
Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 400
Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 402
Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 404
Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 406
Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 408
Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 410
Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 412
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 414
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 416
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 418
Pfizer Completes Public Offering Of Notes Due 2044 For USD500 Million 420
Pfizer Completes Public Offering Of Notes Due 2017 For USD1 Billion 422
Pfizer Completes Public Offering Of Floating Rate Notes Due 2017 For USD500 Million 424
Pfizer Completes Public Offering Of Due 2024 For USD1 Billion 426
Pfizer Completes Public Offering Of Notes Due 2019 For USD1.5 Billion 428
Pfizer Completes Public Offering Of Notes Due 2018 For US$1 Billion 430
Pfizer Completes Public Offering Of Notes Due 2017 For US$750 Million 432
Pfizer Completes Public Offering Of Notes Due 2018 For US$500 Million 434
Pfizer Completes Public Offering Of Notes Due 2023 For US$1 Billion 436
Pfizer Completes Public Offering Of Notes Due 2043 For US$750 Million 438
Medivation Completes Public Offering Of 2.625% Convertible Senior Notes Due 2017 For US$259 Million 440
Biogen Acquires CIAS Asset from Pfizer for up to USD590 Million 442
CordenPharma to Acquire API Manufacturing Facility from Pfizer 443
Avara Pharma to Acquire Sterile Manufacturing from Pfizer 444
ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 445
Pfizer May Sell its Portfolio of Drugs 447
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 448
Novartis Acquires Rights of PF-06438179 from Pfizer 449
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 450
Fareva Acquires Two Production Facilitites from Pfizer 451
Vidhi Research to Acquire Thane Plant from Pfizer for USD27 Million 452
Alvogen to Acquire Four Pharma Products from Pfizer 453
XRpro Sciences Acquires Certain Assets of Icagen from Pfizer 454
R-Pharm Acquires Production Plant in Illertissen, Germany from Pfizer 456
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 457
Fareva Acquires Production Site from Pfizer 458
UPM Pharma To Acquire Manufacturing Facility In Bristol From Pfizer 459
Neolpharma Completes Acquisition Of Manufacturing Plant In Puerto Rico From Pfizer 460
Labrys Biologics Acquires RN-307 from Pfizer 461
Nuron Biotech Acquires Meningitis C Vaccine, Meningitec From Pfizer 462
Sinoxa Pharma Acquires Patent Rights To 5-HT2A+2B Antagonists From Pfizer 463
Tris Pharma Acquires NextWave Pharma 464
Sapphire I (HK) Holdings Acquires 49% stake in Hisun-Pfizer Pharma 465
Paratek Pharma May Sell Itself 466
Pfizer May Sell 40% Stake in Laboratorio Teuto Brasileiro 468
Pfizer Acquires 50% Stake in IGNITE Immunotherapy 469
Pfizer Acquires Medivation in Tender Offer 470
Pfizer Acquires Bamboo Therapeutics 472
Teva Pharma, Mylan May Acquire Teut|Pfizer 473
Pfizer Acquires Anacor Pharma for USD5.2 Billion 475
Pfizer Acquires Treerly Health from Sirio Pharma 477
Pfizer Acquires Hospira for USD16.1 Billion 478
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 480
Pfizer Acquires Minority Stake in AM-Pharma 481
Pfizer May Increase Bid to Acquire AstraZeneca 482
Pfizer Acquires Controlling Interest in Redvax 484
Pfizer Acquires InnoPharma for USD360 Million 485
Pfizer May Acquire Actavis 486
Pfizer May Acquire Bristol-Myers Squibb 487
Biocad Rumored To Sell Itself For Up To US$1 Billion 488
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 489
Pfizer Rumored To Acquire Rexahn Pharma 491
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 492
Nestle Completes Acquisition Of Pfizer Nutrition From Pfizer For US$11.85 Billion 494
Pfizer Completes Acquisition Of NextWave Pharma, Attention-Deficit Drug Maker, For Up To US$700 Million 496
Pfizer Acquires Alacer, Vitamin Supplements Company 498
Pfizer Inc, Key Competitors 499
Pfizer Inc, Key Employees 500
Pfizer Inc, Subsidiaries 502
Pfizer Inc, Joint Venture 525
List of Figures
Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25
Pfizer Inc (PFE)：製薬・医療：M&Aディール及び事業提携情報 |
◆英語タイトル：Pfizer Inc (PFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9916
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：682
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
【レポートの概要】
◆商品コード：DATA904C9916
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：682
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
| Single User（1名様閲覧用） | USD250 ⇒換算￥37,000 | 見積依頼/購入/質問フォーム |
| Site License（同一事業所内共有可） | USD500 ⇒換算￥74,000 | 見積依頼/購入/質問フォーム |
| Enterprisewide License（複数事業所内共有可） | USD750 ⇒換算￥111,000 | 見積依頼/購入/質問フォーム |
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, immune disorders and rare diseases, besides vaccines. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription medicines through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
Pfizer Inc (PFE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
【レポートの目次】
| ★海外企業調査レポート[Pfizer Inc (PFE)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら |
